ADC Therapeutics Gets $50M for Antibody-Drug Conjugates
By Cormac Sheridan
Wednesday, March 28, 2012
Start-up firm ADC Therapeutics Sarl has secured funding commitments of up to $50 million to take forward 10 antibody-drug conjugate programs in oncology, based on conjugate and linker chemistry developed by London-based Spirogen Ltd.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.